Pharmafile Logo

News and Press Releases

MicrosensDx collaborates with Imperial researchers to develop groundbreaking sepsis test

11 September 2024 -- Cambridge, UK -- MicrosensDx is excited to announce that it is working with The Mayr Group at Imperial College London to develop a novel biomarker test...

Category: Biotechnology, Other
Posted: September 11, 2024

MicrosensDx
info@microsensdx.com
204 Cambridge Science Park, Milton Road, Cambridge, CB4 0GZ

Nuclera Awarded £1.14m Innovate UK Funding for Development of eProtein Discovery

£790,000 FASST grant, in collaboration with DeepMirror, and £350,000 Engineering Biology grant awarded for platform development 6 June 2024 -- Cambridge, UK -- Nuclera, the biotechnology company accelerating protein expression...

Category: BioManufacturing, Biotechnology, Drug Discovery, Pharmaceutical
Posted: June 6, 2024

Nuclera
hello@nuclera.com
One Vision Park, Station Road, Impington, Cambridge, CB24 9NP

Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics 11 March 2024 -- Dundee, UK --...

Category: Drug Discovery
Posted: March 11, 2024

Ubiquigent
services@ubiquigent.com
University Incubator Dundee Technopole James Lindsay Place Dundee DD1 5JJ Scotland, UK

Ubiquigent collaborates with Imperial College London on DUB probe discovery to facilitate preclinical and clinical target engagement studies

Sponsored PhD student will join Professor Ed Tate’s group at Imperial College London, UK, in the EPSRC Centre for Doctoral Training in Chemical Biology Project aims to develop the next...

Category: Biotechnology, Drug Discovery
Posted: October 4, 2023

Ubiquigent
services@ubiquigent.com
University Incubator Dundee Technopole James Lindsay Place Dundee DD1 5JJ Scotland, UK